Metraipolis › archive › dc_344d3d0eee83

TROP2-targeting antibody-drug conjugates in breast cancer and ovarian carcinoma: therapeutic advances and resistance mechanisms — Europe PMC PMID:42040770

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42040770
DOI
10.20517/cdr.2025.195
License (as archived)
solo-consultazione
Archived
2026-11-05T12:03:49.258Z
SHA-256 of the archived text
7260c42f17da624427a72d74b58fe1fe52a9016a8090c4c1ab6fe9c8f3806a75
Stable URL of this page
https://metraipolis.com/documento/dc_344d3d0eee83

How to cite

TROP2-targeting antibody-drug conjugates in breast cancer and ovarian carcinoma: therapeutic advances and resistance mechanisms — Europe PMC PMID:42040770 — Europe PMC (en), https://europepmc.org/article/MED/42040770 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_344d3d0eee83 (Metraipolis archive dc_344d3d0eee83, sha256 7260c42f17da624427a72d74b58fe1fe52a9016a8090c4c1ab6fe9c8f3806a75)
BibTeX
@misc{dc344d3d0eee83,
  title = {TROP2-targeting antibody-drug conjugates in breast cancer and ovarian carcinoma: therapeutic advances and resistance mechanisms — Europe PMC PMID:42040770},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42040770},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_344d3d0eee83; sha256 7260c42f17da624427a72d74b58fe1fe52a9016a8090c4c1ab6fe9c8f3806a75},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42040770. Agents can read the archived copy with the MCP tool read_document.